MedTrace Logo

Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

NCT04997148 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2024-12-18

Study results available
· View outcomes & findings →

Summary

The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Merck Serono Limited, UK

    collaborator INDUSTRY

  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2023-09-14
Completion
2023-09-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997148 on ClinicalTrials.gov